PubMed:32471903 / 1465-1686 JSONTXT

{"project":"LitCovid-OGER-BB","denotations":[{"id":"T22","span":{"begin":23,"end":32},"obj":"CHEBI:35222"},{"id":"T23","span":{"begin":23,"end":32},"obj":"CHEBI:35222"},{"id":"T24","span":{"begin":39,"end":42},"obj":"PR:000000134"},{"id":"T25","span":{"begin":160,"end":172},"obj":"CHEBI:35718"},{"id":"T26","span":{"begin":160,"end":172},"obj":"CHEBI:35718"}],"namespaces":[{"prefix":"NCBITaxon","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"}],"text":"Tumour necrosis factor inhibitor (anti-TNF) use was associated with a reduced odds of hospitalisation (OR 0.40, 95% CI 0.19 to 0.81), while no association with antimalarial use (OR 0.94, 95% CI 0.57 to 1.57) was observed."}

{"project":"Inflammaging","denotations":[{"id":"T15","span":{"begin":0,"end":221},"obj":"Sentence"},{"id":"T15","span":{"begin":0,"end":221},"obj":"Sentence"}],"text":"Tumour necrosis factor inhibitor (anti-TNF) use was associated with a reduced odds of hospitalisation (OR 0.40, 95% CI 0.19 to 0.81), while no association with antimalarial use (OR 0.94, 95% CI 0.57 to 1.57) was observed."}

{"project":"hydroxychloroquine","denotations":[{"id":"T1","span":{"begin":0,"end":6},"obj":"Phenotype"}],"attributes":[{"id":"A1","pred":"hp_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/HP_0002664"}],"text":"Tumour necrosis factor inhibitor (anti-TNF) use was associated with a reduced odds of hospitalisation (OR 0.40, 95% CI 0.19 to 0.81), while no association with antimalarial use (OR 0.94, 95% CI 0.57 to 1.57) was observed."}